Atractylenolide III for central nervous system disorders: a review of multi-target mechanisms and therapeutic
Han Li1,2, Ning-Xi Zeng3, Lei Ge2
1Shenzhen Bao'an Chinese Medicine Hospital, The Seventh Clinical College of Guangzhou University of Chinese Medicine, Shenzhen, China.
Abstract:
Central nervous system disorders (CNSDs) are a leading cause of global mortality and disability, yet treatment options remain limited. Natural compounds derived from traditional Chinese herbs constitute a vital resource for discovering novel neuroprotective agents. Atractylenolide III (ATL-III), a sesquiterpene lactone isolated from the spleen-fortifying herb Atractylodes macrocephala Koidz., exhibits neuroprotective properties and possesses the ability to cross the blood-brain barrier (BBB). However, a systematic summary of its effects on CNSDs is currently lacking. This review therefore aimed to comprehensively summarize the therapeutic effects and underlying mechanisms of ATL-III against various CNSDs, and to provide insights for future clinical translation. A systematic literature search was conducted using PubMed, Web of Science, Google Scholar, China National Knowledge Infrastructure, and Wanfang Database for studies published or available online between 1 January 2016, and 31 December 2025. The compiled evidence demonstrates that ATL-III is effective in preclinical models of cognitive impairment, cerebral ischemia/reperfusion injury, depressive disorder, and spinal cord injury. Its neuroprotective mechanisms are multifaceted, involving the enhancement of neurotransmitter storage, reduction of neurotoxic protein accumulation, and exerting anti-apoptotic, anti-inflammatory, antioxidant, and autophagy-regulating effects, alongside BBB repair. In conclusion, ATL-III exerts broad neuroprotective effects through multi-target mechanisms, highlighting its promise as a therapeutic candidate for CNSDs. To realize this potential, key future efforts should include: (1) conducting definitive clinical trials to establish its efficacy and safety profile; (2) comprehensively elucidating its pharmacological and toxicological properties; and (3) developing novel delivery strategies to enhance its bioavailability, BBB penetration, and brain retention.
Related Concept Videos
Drugs Affecting Neurotransmitter Release or Uptake
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Drugs Affecting Neurotransmitter Synthesis
Antidepressant Drugs: MAOIs and Other Agents

